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Abstract
The human SOD1G93A transgenic mouse has been used extensively since its development in 1994 as a model for amyotrophic
lateral sclerosis (ALS). In that time, a great many insights into the toxicity of mutant SOD1 have been gained using this and
other mutant SOD transgenic mouse models. They all demonstrate a selective toxicity towards motor neurons and in some
cases features of the pathology seen in the human disease. These models have two major drawbacks. Firstly the generation of
robust preclinical data in these models has been highlighted as an area for concern. Secondly, the amount of time required for
a single preclinical experiment in these models (3–4 months) is a hurdle to the development of new therapies. We have
developed an inbred C57BL/6 mouse line from the original mixed background (SJLxC57BL/6) SOD1G93A transgenic line and
show here that the disease course is remarkably consistent and much less prone to background noise, enabling reduced
numbers of mice for testing of therapeutics. Secondly we have identified very early readouts showing a large decline in motor
function compared to normal mice. This loss of motor function has allowed us to develop an early, sensitive and rapid
screening protocol for the initial phases of denervation of muscle fibers, observed in this model. We describe multiple,
quantitative readouts of motor function that can be used to interrogate this early mechanism. Such an approach will increase
throughput for reduced costs, whilst reducing the severity of the experimental procedures involved.
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Introduction
Since 1994, transgenic mice expressing high levels of mutated
human SOD1 have been used as a model of amyotrophic lateral
sclerosis [1]. These mice replicate the selective vulnerability of
motor neurones seen in the human disease. Muscle fibres become
denervated, axons degenerate and spinal motor neurones undergo
cell death [2]. Despite sprouting and partial re-innervation of
muscle fibres by slow motor neurones [1,3], muscle volume
decreases [4] with increasing paralysis to the point where humane
intervention is required.
Many advances in our understanding of ALS have emerged from
studies in mutant SOD1 transgenic mice. In this model, various
pathologic changes andmechanisms have been elucidated including
mitochondrial abnormalities [5], oxidative stress [6,7] glutamatergic
toxicity [8,9], cytoskeletal dysfunction [1,10,11,12,13], defective
axonal transport [13,14,15] and repeated denervation and
reinnervation of neuromuscular junctions [2,3,16,17].
Although studies in human ALS patients are critical, one
weakness of such experiments is the requirement to use post-
mortem CNS material collected at the end stage of disease. An
obvious advantage of studies in mouse models is the availability of
CNS material throughout the lifespan of the mice. Genetic
manipulation enables testing of novel hypotheses, for example,
targeted expression of mutant SOD and the use of chimaeric mice
has shown that expression of mutant SOD1 in astrocytes and
microglia is an important driving force in disease progression [18].
The other major application of these murine models is in
preclinical testing of new therapies. The utility of these mouse
models for this purpose has been called into question [19]. Many
drugs and therapeutic approaches have been tested, with the
majority of interventions reported showing relatively mild effects
and translation of these therapeutic benefits to the human disease
has so far been unsuccessful [20]. Much of the criticism has been
leveled at the poor quality of the preclinical study design. The ALS
therapy development institute (ALSTDI), a non-profit organisa-
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tion established to rapidly screen potential therapies in the
SOD1G93A mouse model, have tested .70 compounds in 221
studies using over 18, 000 mice [21]. They have been unable to
replicate any of the published positive effects of compounds in this
model. Using their own data to identify possible sources of noise
and bias, they concluded that the majority of published positive
neuroprotective effects were in fact due to biological noise and
poor study design [21].
The 142nd European NeuroMuscular Centre Workshop on
‘Guidelines on Preclinical models of ALS’ adopted the ALSTDI
recommendations for the conduct of pre-clinical studies which
included the use of litter matched control and treatment groups, n
numbers of 24 per group, gene copy number analysis for all mice
on therapeutic trials and the censoring of data from littermates of
mice which are lost from the study due to non-ALS related events
[22]. These guidelines have been recently updated to include a
checklist for reviewers and journal editors when assessing studies in
this model [23].
The commonly used SOD1G93A strain is maintained by crossing
hemizygous male transgenic mice with female C57BL66SJL/J
hybrids. This leads to genetic variation in these mice and genetic
variation is known to increase variability in biological readouts.
The best way of avoiding this noise is to use well defined inbred
mouse strains [24,25]. We have pursued a strategy of using the
SOD1G93A transgenic mice on an inbred, C57BL/6 genetic
background to minimise genetic variation and enhance the quality
of data generated in this model. We have gathered data in multiple
therapeutic trials using a newly developed behavioural assessment
protocol and show here that our model is very consistent across
studies and less variable than the published data for the models on
a mixed genetic background, reducing biological noise and
consequently the number of mice required to reach statistical
significance in efficacy studies.
We have also detected early behavioural changes (reduced
rotarod performance) prior to the previously reported onset of
clinical signs, which correlate remarkably well with the described
pattern of early dennervation and re-innervation described in this
model [3]. This has led to the development of further quantitative
measures of early disease progression (automated gait analysis and
quantification of hind limb muscle volume using magnetic
resonance imaging) and the design of a ‘rapid early’ screening
protocol. This refinement has the combined benefit of being faster,
less resource intensive and less distressing to the mice, satisfying the
underlying principles of UK regulated animal research which is
embodied in the principles of reduction, refinement and replace-
ment (the 3Rs) first proposed by Russell and Burch [26]. In addition
it enables precise evaluation of therapeutic benefit with respect to
the early denervation seen in this model and also described in man
[2]. We expect that our approach and the model that we have
generated will be of value to the ALS research community, helping
to accelerate development of therapeutic candidates for effective
clinical translation and will inform approaches to pre-clinical testing
in other neurological disease areas also.
Results
We conducted six pharmacology studies in the C57BL/6
SOD1G93A transgenic mouse model of ALS over a two year
period, representing five small molecule drug studies and one gene
therapy study. The details of each study are shown in table 1 and
the vehicle control groups were used for the analysis of variability
below. At the outset we applied principles of good experimental
design based on publications such as ‘The Design of Animal
Experiments’ [27]. We were also aware of the need to monitor
transgene copy number in our studies, as reductions in copy
number can occur within breeding colonies and significantly alter
expression of the disease course. Indeed, transgene copy number
correlates directly with survival [28]. We routinely collected data
for transgene copy number in male breeders and in all mice on
pharmacology studies initially. No significant variation was
observed for mice on pharmacology studies, however, reduction
in copy number was detected in the breeding colony on two
occasions (,1/year). These mice were identified readily by their
phenotype at 90 days of age. Since these events were rare and
easily identified by phenotype, we have subsequently only
conducted copy number analysis where a reduced copy number
is suspected from the phenotype.
We included a number of readouts, including motor function
(rotarod test), weight, disease onset (first signs of tremor and hind-
limb splay defect) and survival (loss of righting reflex for more than
10 seconds or 30% weight loss for 72 h) as well as scoring the
overall distress level in mice from 125 days of age onwards. These
readouts were kept as standardised as possible from study to study
to allow for qualitative comparisons of data between studies. This
approach has allowed us to make two useful observations.
The disease course is remarkably consistent
Data in table 2 show the average age at onset and end-point for
the vehicle control group in each individual study and the average
time taken for mice to show an initial 20% decline in rotarod
performance. This data is shown for the whole group and is also
broken down by sex. The studies are numbered according to the
reference numbers in table 1. The data for onset and survival show
very low within-study (intra-study) variability as shown by the low
coefficient of variation (CV- standard deviation as a percentage of
mean). The CV for onset ranges from 3.8% to 6.9% and for
survival from 3.8% to 4.7%. For end-stage, the standard deviation
is approximately 6 days compared to the average standard
deviation seen for the mixed background (SJLBL6) model of 10
days [21]. The impact of this seemingly small difference on study
design is large. Power analysis using GraphPad Statmate, shows
that to detect a difference of approximately 10% in survival times
using a Students’ T test would need an n of 17 per group for an SD
of 10 compared to an n of 7 for an SD of 6 days. The survival data
also show excellent between study (inter-study) variability with a
coefficient of variation of 1.7% across the studies listed in table 2.
The inter-study variability for the onset data is higher at 5.0%,
possibly reflecting variation between scorers for this subjective
assessment. There are no significant differences between males
and females for any of the parameters measured although female
mice show a trend to reduced variability in the various readouts.
This is particularly true for the rotarod data where female mice
show a two-fold or more reduction in variability for time to reach a
20% reduction in rotarod performance in 4 out of 5 studies. The
rotarod data are the most variable and there is the possibility of a
time-related change in rotarod performance with studies 1 and 2
showing an average age at 20% decline in rotarod performance of
less than 50 days and studies 4, 5 and 6 showing an average of
57.6, 58.3 and 52.0 days respectively. Whether this reflects a time-
dependent change in measurement of this parameter or simply
variability around the true mean is difficult to ascertain.
Motor deficits are detectable very early and correlate
with published patterns of synaptic remodelling at motor
end plates
The data in table 2 show that SOD1G93A transgenic mice
exhibit a very early decline in rotarod performance, with a 20%
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reduction in performance from baseline occurring by day 50–60.
These data are more variable than the onset and survival data -
the coefficient of variation ranges from 9% to 25.8%. When the
rotarod data for individual studies are plotted (figure 1) a very
obvious rapid decline in rotarod performance is observed from
approximately 45 days of age. These data are generated after the
training period, and so do not represent acclimatisation to the
apparatus. Rotarod performance generally increases in the three
successive training runs (data not shown). Littermate control non-
transgenic (NTG) mice do not show the same pattern of decline
and indeed at the earliest timepoint shown here, they are already
outperforming their SOD1G93A transgenic littermates. Overlay of
the rotarod data in figure 1 also highlights another interesting
feature. It appears that the rate of decline abruptly slows at around
60 days of age. This rapid decline followed by a levelling off
correlates with the recently described denervation of fast-fatigable
fibres (days 48 to 52) followed by their re-innervation and
conversion to fast non-fatigable fibres from day 60 onwards [3].
The authors of this study also described a second loss of
innervation for these fast non-fatigable fibres between days 80 to
90 of age which correlates with a further decline in rotarod
performance seen here (see figure 1).
Neuromuscular Junction (NMJ) Histology
In order to confirm that this early decline in motor function
correlated with an early loss of innervation of motor end-plates in
the gastrocnemius muscle, we performed dual immunofluores-
cence staining of nicotinic acetycholine receptors(AChR) with a-
bungarotoxin and axonal end-feet with anti-neurofilament anti-
bodies and quantified the percentage of post-synaptic processes
showing some degree of axonal co-localisation (figure 2). Overall
there was an almost 60% loss of co-localised staining in SOD1G93A
transgenic mice at 60 days of age compared to non-transgenic
mice of the same age. (NTG 96.4+/22.5%; SOD1G93A 37.4+/
28.5%, p,0.0001, Student’s T test).
Given that significant motor function decline associated with an
early process of NMJ loss was observed in our model, we
postulated that it would be possible to detect the therapeutic effects
of interventions at a much earlier stage than had previously been
described, providing disease progression could be measured in a
Table 1. Summary of the control group data in the C57BL/6 SOD1G93A transgenic mice.
Study reference
number Dose Route and frequency N
Age at
first dose Start date
1 Vehicle Once daily gavage (10 ml/kg) 9 45 13/4/05
2 Vehicle Intraperitoneal, 3/week (5 ml/kg) 13 45 13/05/05
3 Vehicle Once daily gavage (10 ml/kg) 10 75 14/7/05
4 Vehicle In water (continuously) and subcutaneous (3/week, 5 ml/kg) 12 45 23/02/06
5 Control virus Multiple intramuscular injections (120 m1 total, 5 ml/site), once at 21 days of age 10 21 10/10/06
6 Vehicle Chow continuously 11 25 23/03/07
A total of 6 therapeutic studies were performed in the C57BL/6 SOD1G93A transgenic mouse model of ALS over approximately 2 years. Reference number refers to the
data shown in table 2 and figure 1. Studies were conducted according to a standardised protocol as described in the materials and methods.
doi:10.1371/journal.pone.0023244.t001
Table 2. Reproducibility between studies.
Trial Number
1 2 3 4 5 6
m f all m f all m f all m f all m f all m f all
Onset (age
in days)
74.0
(65.2)
74.8
(63.7)
74.4
(±4.7)
nd nd nd 77.8
(65.1)
74.2
(64.6)
75.6
(±4.9)
72.5
(65.5)
76.3
(62.9)
73.5
(±5.1)
72.4
(64.7)
74.4
(62.5)
73.4
(±3.7)
65.9
(62.2)
68.5
(63.5)
66.4
(2.6)
CV (%) 7.0 4.9 6.4 6.6 6.2 6.5 7.5 3.8 6.9 6.4 3.4 5.0 3.3 5.2 3.8
Survival (age
in days)
nd nd nd 138.7
(66.6)
134.0
(65.4)
136.8
(66.4)
142.0
(67.1)
144.7
(65.3)
143.6
(±6.1)
138.5
(65.3)
142.7
(63.9)
139.6
(±5.3)
136.6
(67.2)
142.0
(63.1)
139.3
(±6.0)
140.4
(66.6)
136.5
(60.7)
139.6
(±6.0)
CV (%) 4.3 4.7 4.7 5.0 3.7 4.2 3.8 2.7 3.8 5.3 2.2 4.3 4.7 0.5 4.3
Rotarod
(age at 20%
reduction)
48.8
(68.7)
47.6
(64.0)
48.2
(±6.4)
48.7
(64.6)
44.6
(62.2)
47.0
(64.2)
nd nd nd 56.5
(611.4)
60.7
(69.1)
57.6
(±10.5)
59.6
(621.2)
57.0
(67.5)
58.3
(±15.0)
55.3
(611.0)
46.7
(63.5)
52.0
(±10.1)
CV (%) 17.9 8.4 13.3 9.5 4.9 9.0 20.1 15.0 18.3 35.5 13.2 25.8 19.8 7.5 19.1
Data shown are for the entire control group (all) for six independent efficacy studies in the SOD1G93A transgenic mouse model of ALS, as well as the data for male (m)
and female (f) mice in each study. Study details are given in table 1. Each parameter is measured in age (days) +/2 standard deviation. ‘Onset’ is age in days at which
both hind-limb splay and tremor were first obvious; ‘Survival’ is age in days to humane end-point (loss of righting reflex for more than 10 seconds or weight loss of
.30% for .72 hours), ‘Rotarod’ is the age in days at which a 20% reduction in rotarod performance compared to baseline was first seen. For each parameter the
coefficient of variation (CV) is also shown. This is the standard deviation expressed as a percentage of the mean. These parameters are not comparable either because
different criteria were applied or the data were not collected; nd-not determined, nk-not known.
doi:10.1371/journal.pone.0023244.t002
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robust and quantitative manner. To this end we assessed
additional measures of disease progression using quantitative gait
analysis and magnetic resonance imaging of hind-limb muscle
volumes.
Gait Analysis
We embarked on a gait analysis study in a cohort of SOD1G93A
mice and NTG control mice using the Catwalk gait analysis system
from Noldus Instruments [29]. A group of 5 SOD1G93A mice and
7 age-matched NTG mice were assessed at weekly intervals from
35 days of age. The system allows for automated analysis of gait
parameters following video capture and manual segmentation of
step patterns. The results for 42 different gait parameters are
shown in table 3 as the raw P values for the difference between
SOD1G93A mice and NTG mice using a Students’ T test at each
timepoint, for each parameter. The P value required for
significance after Bonferroni correction is ,0.00011 and the P
values below this threshold are highlighted in bold.
This analysis indicated that there were some parameters
showing small but significant changes at early time-points,
although the majority of changes appeared after the onset of
visible clinical signs (,74 days) indicating that gait analysis is not
as sensitive as the rotarod test for detection of early motor deficits
in this model. Some of the altered gait parameters are shown in
figure 3. Stand time is the duration of the stance phase for a
particular limb in seconds and this is marginally increased at 63
and 105 days in SOD1G93A mice (63days; 0.016seconds in NTG
vs 0.1560.02 mm in SOD1G93A, p,0.05, 105 days; 0.146
0.02 seconds in NTG vs 0.1560.02 mm in SOD1G93A, p,0.001,
two-way ANOVA with Bonferroni post-test). The most commonly
assessed gait parameter in mouse models of ALS is stride-length
and significant differences in stride length of hind-limbs were seen
at 84 and 105 days of age (figure 3b 84 days; 53.068.3 mm in
Figure 1. SOD1G93A mice on a C57BL/6 background show a
consistent, early decline in rotarod performance. Rotarod
performance measured as time to fall in seconds (y axis, scale bar at
left) +/2 standard error of the mean (vertical bars) against age in days
for six control groups from independent efficacy studies in the
SOD1G93A transgenic mouse model of ALS. Study details are given in
table 1. The data are offset to allow comparison of the individual curves,
the number at the left hand side of the curve is the average time in
seconds for the first data point. Also shown are data from a group of
control animals (non-transgenic littermates of mice in study number 6)
and a plot of the average data for the six control groups (average).
Curves are labelled at the right hand side with study number, ‘control’
and ‘average’. A dotted reference line is shown at 60 days, where the
rate of decline in performance slows considerably for most studies.
doi:10.1371/journal.pone.0023244.g001
Figure 2. Quantification of neuromuscular junction (NMJ)
innervation at 60days in SOD1G93A transgenic mice. (A, B)
Immunofluorescence staining of gastrocnemius muscle with a-Bunga-
rotoxin (red) and anti-neurofilament antibodies (green). NMJ were
counted as innervated when end-plates showed overlap of neurofila-
ment and AChR staining (A, image from a non-transgenic mouse) and
denervated when endplates showed absence of neurofilament labeling
(B image from a SOD1G93A transgenic mouse). Scale bar 50 mM. The
percentage of a-Bungarotoxin stained end-plates showing complete
and partial co-localisation of neurofilament staining versus absence of
colocalisation (C) is shown for 5 non-transgenic mice (NTG) and 5
SOD1G93A transgenic mice (G93A) at 60 days of age. Average +/
2standard deviation is shown (NTG 96.4+/22.5%; G93A 37.4+/28.5%,
p,0.0001, Student’s T test). Graph displays result for individual animals.
Median horizontal line indicates the mean value. Upper and lower
horizontal lines linked by a vertical line show SD.
doi:10.1371/journal.pone.0023244.g002
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NTG vs 42.062.1 mm in SOD1G93A, p,0.05, 105 days;
55.364.2 mm in NTG vs 39.766.1 mm in SOD1G93A,
p,0.001, two-way ANOVA with Bonferroni post-test). Gait
patterns were also disturbed, with SOD1G93A mice progressively
spending less time supporting themselves with diagonal limbs
(figure 3c) with a concomitant increase in the use of three limbs to
support their weight (figure 3d), which may reflect a reduced
stability of gait. It is interesting to note that some of the gait
parameters show initial changes only to recover later on, whilst
some of this may be attributable to noise, it may also be the case
Table 3. Raw P values (Students’ T test) for 42 different gait parameters in SOD1G93A mice vs NTG mice.
Age (days) 35 42 50 56 63 70 77 84 91 98 105
Intensity - fore paws 0.034 NS 0.0207 0.0083 NS NS NS NS 0.0175 0.0323 NS
Intensity - hind paws NS NS NS NS 0.0202 0.0453 0.0317 0.0043 ,0.0001 ,0.0001 ,0.0001
Print Width - fore paws NS 0.0078 0.0172 NS NS NS NS 0.0217 0.0088 0.0016 0.0002
Print Width - hind paws NS NS NS NS NS NS NS NS NS NS 0.0185
Print Length - fore paws NS 0.0011 ,0.0001 0.0005 NS NS NS NS 0.0492 0.0244 0.0109
Print Length - hind paws NS 0.0408 NS NS NS NS NS NS NS NS NS
Print Area - fore paws NS NS 0.0213 0.0014 NS NS NS 0.0326 0.0399 0.0034 0.0001
Print Area - hind paws NS NS NS 0.0169 NS 0.002 0.0113 NS 0.0463 NS NS
Stand time - forelimb NS NS ,0.0001 NS ,0.0001 NS ,0.0001 0.001 0.0001 0.0009 ,0.0001
Stand time - hindlimb NS NS 0.0074 NS ,0.0001 NS 0.0016 NS 0.0001 0.0021 0.0001
Paw angle - fore paws NS NS NS NS NS NS NS 0.0477 NS NS NS
Paw angle - hind paws NS NS NS NS NS NS NS 0.0465 NS NS NS
Swing - forelimb NS NS NS NS 0.0314 NS NS NS 0.0278 0.0097 0.002
Swing - hindlimb NS NS NS NS NS NS 0.0061 NS NS 0.05 NS
Stride length - front NS NS NS NS 0.039 NS NS 0.0036 0.0045 0.0002 ,0.0001
Stride length - back NS NS NS NS 0.0339 NS NS 0.0005 0.0003 ,0.0001 ,0.0001
Duty cycle - forelimbs NS NS ,0.0001 0.0195 0.0073 NS NS 0.0001 ,0.0001 ,0.0001 ,0.0001
Duty cycle - hindlimbs 0.0415 NS NS NS 0.0181 NS NS 0.0053 ,0.0001 0.0007 0.0001
Max contact at % - fore paws NS NS NS NS NS NS NS NS NS NS 0.0088
Max contact at % - hind paws NS NS NS NS NS NS NS NS NS NS 0.0055
Swing speed - fore limb NS NS NS NS NS NS NS NS NS NS NS
Swing speed - hind limb NS NS 0.0228 NS NS NS NS 0.0193 NS NS NS
Stand index - fore limb NS NS 0.0011 NS 0.0044 NS NS 0.0117 0.0202 0.0416 0.0193
Stand index - hind limb NS NS 0.0053 NS NS NS NS NS NS NS 0.0052
Duration NS NS NS NS NS NS 0.0322 NS NS 0.0412 0.037
Step pattern # NS 0.0173 NS NS NS NS NS 0.0248 0.0034 NS 0.0051
Step pattern Ca 0.0414 NS NS NS NS NS NS NS NS NS NS
Step pattern Cb NS NS NS 0.0372 NS NS NS NS 0.0041 0.0039 0.0088
Step pattern Aa NS NS NS NS NS NS 0.0211 NS 0.0019 0.018 0.0002
Step pattern Ab NS NS NS NS NS NS 0.0353 NS 0.0001 0.0005 ,0.0001
Regularity Index NS NS NS NS NS NS NS NS NS NS 0.0002
Base of support - front NS NS NS NS NS NS NS NS NS NS NS
Base of support - hind NS NS NS NS NS NS NS NS 0.0156 0.003 0.0027
Print position - right NS 0.0012 NS NS NS NS NS NS NS NS NS
Print position - left NS 0.0214 NS NS NS NS NS NS NS NS NS
Support - zero NS NS NS NS NS NS NS NS NS NS NS
Support - single NS NS 0.017 NS NS NS NS NS NS NS NS
Support - diagonal NS NS NS NS 0.0013 NS 0.0303 0.0095 ,0.0001 ,0.0001 ,0.0001
Support - lateral NS NS NS NS NS NS NS NS NS NS NS
Support - girdle NS NS NS NS NS NS NS NS NS NS NS
Support – 3 limbs NS NS NS NS 0.0024 NS 0.0353 NS 0.0037 0.0003 ,0.0001
Support – 4 limbs NS NS NS NS 0.0199 NS NS 0.0036 0.021 0.0215 0.0286
Gait parameters for SOD1G93A mice and non-transgenic (NTG) mice were determined using the Catwalk system. Gait was assessed at weekly intervals. P values
highlighted in bold are less than the required P value of ,0.00011 following a Bonferroni correction.
doi:10.1371/journal.pone.0023244.t003
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that dennervation followed b reinnervation [3] is responsible
for a loss and then recovery reflected in the changing significance
levels.
MRI Imaging of hind-limb muscle volume
An MRI study was conducted to assess lower hind-limb
muscle volumes in five SOD1G93A transgenic mice and five litter
matched NTG mice at 30, 60, 90 and 120 days of age.
Structural (T2 weighted) MRI scans of hindlimbs were used to
determine lower limb volume (figure 4). Significant differences
between SOD1G93A transgenic mice and NTG littermates were
observed at all timepoints. At 30 days these may reflect overall
differences in size between NTG and SOD1G93A mice but the
changes thereafter appear to be due to muscle atrophy. In the
SOD1G93A mice, average lower limb volume reduced by 5%
between 30 and 60 days, 33% between 30 and 90 days and by
56% between 30 and 120 days. This contrasts with an increase
in muscle volume of 53% between days 30 and 60, 33%
between days 30 and 90 and 56% between days 30 and 120 in
NTG mice.
Discussion
We have shown that the SOD1G93A mouse model of ALS on a
defined background is highly predictable and shows low variability
in a number of readouts, particularly survival. In addition there
are early and significant changes in motor performance which can
be reliably detected. We believe this has important implications for
the testing of therapeutic strategies and for basic investigations of
disease biology in this model. Firstly, use of mice with an
undefined genetic background is well recognised as a potential
confounding issue in preclinical drug screening [30]. Indeed the
use of the hybrid SJLxC57 SOD1G93A transgenic mice has
identified a variety of potentially confounding factors which can
contribute to background noise and lead to false positive effects, if
not adequately controlled, as well as requiring studies with large n
numbers of 24 mice per group [21]. The results we show here for a
significantly reduced variability in time to reach end-stage
correlate with those obtained previously for a defined C57BL/6
background with this transgene [31] where the standard deviation
of the end-point on the C57BL/6 background was 7.5 days
Figure 3. Analysis of individual gait parameters over time in SOD1G93A transgenic mice. Selected gait parameters from table 3 were
subjected to two-way ANOVA with Bonferroni post-tests. Average stand time (a) in seconds, hindlimb stride length (b) in mm, use of diagonal
support (% of time) and use of three limbs for support (% of time) +/2 standard deviation for SOD1G93A mice versus non-transgenic (NTG) control
mice at weekly intervals between 35 and 105 days of age are shown. Asterisks indicate p,0.05 (*), p,0.01 (**) and p,0.001 (***) using bonferroni
post test following two-way ANOVA on raw data (a, b) or logit transformed data (c, d). The majority of differences were detectable post-onset of
classical signs (,75 days).
doi:10.1371/journal.pone.0023244.g003
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compared to 6 days in our model and 11.2 days in the SJLBL6
background [21]. This reduction in variability has a significant
impact on the number of animals required to conduct pharma-
cological studies. It is possible that the variability is influenced by
the precise criteria used to define the end-stage of disease and the
two cited studies used slightly different criteria to define the end-
stage as was used here. Scott et al used ‘‘inability of a mouse to
right itself in 30 s after being place on its side’’, Heiman-Patterson
et al used ‘‘paralysis of one hind limb, or were unable to right
themselves in 30 s when placed on their side’’ whereas we used
‘‘inability to right within 10 seconds of being placed on their back
or weight loss of .30% for 72 hours’’. In practice the time cut-off
for measuring loss off righting reflex (10 s or 30 s) would not be
expected to make a substantial difference in when the end-stage of
disease is recorded, as discussed in the recent ‘Guidelines on
Preclinical models of ALS’ [23]. In addition the weight loss cut-off
used in our criteria was implemented in less than 10% of mice and
again would not be expected to substantially influence the
variability in reaching end-stage. It is possible that a proportion
of the variability may be attributed to these different criteria
however when Heiman-Patterson et al applied the same criteria to
both C57BL/6 and SJLBL6 background SOD1G93A transgenics
there was still a substantial reduction in the SD of time to reach
end-stage [31].
We also show that the between-study variability for this readout
is very low. With a variety of different dosing regimes (table 1), the
inter-study variability for time to reach end-stage is just 1.7%
(CV). This greatly facilitates the identification of real positive
Figure 4. MRI detects muscle atrophy in SOD1G93A transgenic mice. T2 weighted structural scans of hindlimb at 30, 60, 90, 120 days of age
(a) were used to calculate lower limb volume (knee to ankle), n = 5 per group (b), which was significantly reduced in SOD1G93A transgenic mice
compared to non-transgenic (NTG) littermates at all timepoints (p,0.05 at 30 days, p,0.001 at 60, 90, 120 days, two way ANOVA with Bonferroni
post test). The change in lower limb muscle volume as a function of weight (c) is also shown, indicating the initial difference in muscle volume
observed at day 30 may be due to the smaller size of the SOD1G93A transgenic mice.
doi:10.1371/journal.pone.0023244.g004
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effects in our model. In addition, the potentially confounding
differences in survival seen between male and female mice on the
mixed background are not seen in our C57BL/6 line, again
confirmed in a previous study [31]. The only consistent difference
between male and female mice in our studies is that female mice
show substantially reduced variability in time to reach a 20%
reduction in rotarod performance in 4/5 studies (table 2). This is
the opposite of the trend observed in the SJLBL6 line [32] which
again may be explained by strain differences. The reason for this
reduced variability in female C57BL/6 mice is unknown but
gender differences in voluntary wheel-running have been previ-
ously described in C57BL/6 mice [33]. In addition the rotarod
data showed the greatest variability overall both within studies and
between studies.
The second major impact of our findings is that the early defects
in rotarod performance described here bring into question when
‘onset’ actually occurs in this model. Typically a figure of 90 days
is quoted for onset in the C576SJL background as the point at
which visible signs such as tremor and hind-limb splay defects are
detectable. We observe these signs at about 75 days of age in the
C57BL/6 background. Defining onset as the point at which these
crude measures of tremor and hind-limb splay become obvious is
inappropriate in our view. These mice have a very high level of
mutant SOD1 transgene expression and the mice reach end-stage
at about 140 days of age, whereas normal C57BL/6 mice can
enjoy an average lifespan of over 800 days [34]. This suggests the
disease process is aggressive. A review of relevant published work
indicates that many behavioural, electrophysiological and neuro-
pathological changes are occurring in mutant SOD transgenic
mice from the very earliest stages of development (Table 4).
Our data show a robust and reproducible, decline in motor
function as measured by rotarod performance from approximately
40 days of age, over a month prior to the onset of visible clinical
signs of disease, although this parameter is the most variable of
those measured in this study. A reduction in motor performance
has been defined by other groups at similar ages [34,35,36,37],
which correlates with a loss of functional motor units as measured
by electromyography [38] and the onset of denervation of motor
end-plates [2,3,17]. At 60 days of age in our model, the hind-limb
gastrocnemius muscle shows a 60% loss in the number of post-
synaptic sites showing innervation, compared to wild-type mice.
This is a full two weeks prior to the onset of visible signs of tremor
and hind-limb splay defects. These changes correlate with a
substantial reduction in lower limb volume in SOD1G93A
transgenic mice, with a reduction between postnatal days 30 and
60 of 5%, whereas non-transgenic littermates show an increase of
53% in lower hind-limb volume over the same time.
Abnormalities in motor function have been detected even
earlier. A delay in the development of motor reflexes has been
described in both SOD1G85R C57BL/6J and in SOD1G93A
C576SJL mice between postnatal (P) days 1–7 [39,40] suggesting
that the development of the motor system itself is impaired. These
reflexes eventually develop to the level seen in control mice by
around P10. At similar time-points, a variety of studies have
described electrophysiological changes occurring in spinal cord
and motor cortex of mutant SOD transgenic mice [39,40,41]. It is
attractive to hypothesize, as suggested by Amendola et al. [39] that
the motor system compensates for an early defect in development
by some unknown adaptation, but that this adaptation eventually
fails leading to motor neuron degeneration, starting with a dying
back axonopathy.
Early pathological changes that could give some clues to early
disease mechanisms are the presence of vacuoles in dendrites and
mitochondria of motor neurones which occur as early as P14 [42].
Table 4. Summary of studies describing ‘pre-symptomatic’ changes in SODG93A mice.
Process Age Strain Reference
Behavioural/Motor function
Delay in development of righting and hind-paw grasping reflexes P1–7 SOD1G85R C57BL/6J [39]
Delay in development of locomotor abilities P1–7 SOD1G93A C576SJL [40]
Reduced open-field motor function P45 SOD1G93A C57BL/6J [36]
Reduction in muscle strength and co-ordination P56 SOD1G93A C576SJL [35]
Altered gait (treadmill) P56 SOD1G93A C57BL/6J [37]
Electrophysiology
Rhythmic motor activity difficult to induce at lumbar levels ex vivo P1–7 SOD1G85R C57BL/6J [39]
Motor neurones have lower input resistance and higher membrane capacitance P6–10 SOD1G85R C57BL/6J [41]
Hypoglossal motor neurones show increased excitability and synaptic remodelling. Similar changes in
interneurons of the superior colliculus
P4–10 SOD1G93A C576SJL [40]
Decrease in amplitude and conduction velocity, increase in latency in sciatic nerve P20–40 SOD1G93A C576SJL [51]
Loss of functional motor units by electromyography P47 SOD1G93A C576SJL [38]
Neuropathological
Vacuolation and mitochondrial swelling in anterior horn neurones of lumbar spinal cord P14 SOD1G93A C57BL/6J [42]
Increased oxidative stress (protein carbonyl content) in spinal cord P30 SOD1G93A C576SJL [7]
Fragmentation of Golgi apparatus P31 SOD1G93A C576SJL [43]
Significant denervation of motor end-plates in hind-limb muscles P47–50 SOD1G93A C576SJL [2,3,52]
Astrocyte activation (increased glial fibrillary acidic protein (GFAP) staining) in spinal cord P47 SOD1G93A C576SJL [2]
Microglial activation in spinal cord P80 Not stated [53]
Studies showing ‘pre-symptomatic’ defects or changes in motor function, electrophysiology and neuropathology in mutant SOD transgenic mice are detailed. In all
cases the earliest age at which mice show the changes is quoted as the postnatal (P) age in days.
doi:10.1371/journal.pone.0023244.t004
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Of the other major pathways implicated in mutant SOD toxicity,
oxidative stress occurs early, around P30 [7] with fragmentation of
the Golgi apparatus at P31 [43] and early signs of inflammation
such as astrocytic activation occurs around the same time as the
initiation of denervation at P47 [2]. Motor neurones isolated from
embryos of SOD1G93A transgenic mice display impaired fast
axonal transport, highlighting this as one of the earliest
pathological events so far described [15].
Interestingly, quantitative measurement of multiple gait param-
eters did not yield any readouts with a substantial early change in
function at similar time-points to the observed reduction in
rotarod performance. The most robust changes were most obvious
at later stages of the disease process after the onset of visible
clinical signs. The rotarod test assesses a variety of motor and non-
motor functions simultaneously. Co-ordination, balance, strength,
stamina and determination are all probed. Given the preferential
loss of processes innervating fast-fatigable fibres [3] and the
substantial loss of muscle mass, we conclude that muscle strength is
the major determinant of the decline in rotarod performance.
Other groups have described standardised methods for assessing
a variety of motor function readouts in the hybrid SJLBL6
SOD1G93A transgenic mouse [32,44] and have concluded that
rotarod and footprint analysis were the most informative methods
[32] or have identified the optimal timepoint at which to apply
specific tests [44].However they do not offer an alternative early
screening paradigm as described here.
Taken together, the data demonstrate that the disease process is
active from the earliest ages and standard notions of disease onset
should be reconsidered. In view of this, we advocate a screening
protocol based on assessing therapeutics in this early window of
loss of motor function and hind-limb muscle innervation, with a
view to reducing the number of animal experiments which have to
be taken through to phases of disease which cause the most
distress. This approach has an added advantage of allowing a
more rapid assessment of therapeutic utility and requiring fewer
resources in terms of manpower and costly therapeutic reagents.
The following protocol, summarised in figure 5 with power
calculations, is recommended.
1/ Use 14 litter and sex matched mice in each of two groups
(control dosed and active dosed), dosed from day 21 onwards
(weaning), with weighing at each dose.
2/ Assess from day 35 twice per week for motor performance
using rotarod testing following 3 days consecutive training on
,days 30–33.
3/ At day 60 assess hind-limb muscle volumes using MRI in 7
mice per group and collect tissue from the same mice to assess
percentage innervation of motor end-plates in the gastrocnemius
muscle.
4/ Assess the remaining 7 mice per group, 3 times per week for
onset of clinical signs from 60 days of age to day 90 (if necessary)
and gait analysis using the catwalk gait analysis system at 63, 77
and 91 days of age (9, 11, and 13 weeks). Collect tissue at day 91
for further analysis of histological readouts.
This protocol not only allows for reduction of animal numbers
and refinement of the experimental procedure with respect to
animal welfare in line with the principles of the 3Rs, but allows for
assessment of multiple quantitative measures of disease progression
relating to defined neuropathological and physiological changes
occurring in muscle which relate to the underlying pathophysiol-
ogy of the disease.
The main criticism of this approach is that mechanisms active
early in the disease may not be responsible for later progression.
The model we propose allows clearer evaluations of therapeutic
interventions on the onset of muscle denervation. It can be
supplemented by additional studies to determine whether the time
taken to reach end-stage is affected and also if treatment initiated
later in the disease course has a differential effect, but these studies
can be rationally restricted to those therapies which display some
therapeutic benefit in the early stages of disease. We see this
screening paradigm as a tool for accelerating therapeutic
Figure 5. A short term protocol for preclinical pharmacology studies in SOD1G93A transgenic mice. Effects on rotarod performance are
assessed between days 35 to 60, analysis of hind-limb muscle volume and immunohistochemistry to assess the degree of gastrocnemius innervation
at day 60 in half of the cohort and the remaining cohort being assessed for motor function using the catwalk gait analysis system and for time to
onset. The n numbers have been selected on the basis of the data presented in this paper. The most variable readout requiring the largest n is the
time to reach a 20% reduction in rotarod performance with a coefficient of variation (CV) ranging from 9.0% to 26.6% and an average CV of 17%.
Fourteen mice per group are required to detect a shift of 10 days in this initial decline in rotarod performance with a power of 80% (two-tailed
Student’s T test, a= 0.05, b= 0.8). Power analysis shows an n of 7 is sufficient to detect a 20% change in muscle volume assessed using MRI based on
the 60 day data for SOD1G93A mice shown in figure 4, where hind-limb muscle volume was 0.25 cm3+/20.033 (SD) on day 60 (Student’s independent
T test, two-tailed, a= 0.05 and b= 0.8). From figure 3 the percentage of innervated neuromuscular junctions in the gastrocnemius muscle of 60 day
old SOD1G93A transgenic mice was 37.4+/28.5% (SD). Assuming a 15% increase in this level of innervation to 52.4%, an n of 7 per group would give
80% power (b=0.8) at a significance level of 0.05 (Students T test, two-tailed). For onset, 7 mice per group is sufficient to detect a difference of 1
week in onset of clinical signs of disease (two-tailed Student’s T test, a=0.05, b= 0.8). All power analyses were performed with G*Power version 3.0.3.
doi:10.1371/journal.pone.0023244.g005
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assessment in mouse models of ALS using robust and quantitative
methodology with the intention of bringing new therapies to the
clinical arena more rapidly.
Materials and Methods
Ethics Statement
All mouse experiments were carried out in accord with the
Animals (Scientific Procedures) Act 1986 under a UK Home
Office project license number 40/3089, reviewed and approved by
the Sheffield University Ethical Review Committee Project
Applications and Amendments Sub-Committee of the Sheffield
University Ethical Review Committee and by the Animal
Procedures Committee (London, UK). Animals were housed and
cared for according to the Home Office Code of Practice for the
Housing and Care of Animals Used in Scientific Procedures. The
ARRIVE guidelines have been followed in reporting this study
[45].
Transgenic C57BL/6 SOD1G93A model of ALS
Mice were originally obtained from the Jackson Laboratory,
B6SJL-Tg (SOD1-G93A)1Gur/J (stock number 002726) and were
subsequently backcrossed onto the C57BL/6 background (Harlan
UK, C57BL/6 J OlaHsd) for .20 generations to create a line on
an inbred genetic background. As well as reducing variability, this
avoids any complications arising from the presence of a splice-site
mutation in the Dysferlin gene found in the SJL background which
leads to the development of a spontaneous myopathy [46]. The
SOD1G93A transgene is maintained as a hemizygous trait by
breeding hemizygous males with wild-type females (C57BL/6J
OlaHsd, Harlan UK). Hemizygous males for breeding are
available from our facility upon request.
Genotyping and Copy Number Analysis
Mice were identified by ear clipping and the ear tissue was
retained for extraction of genomic DNA using the DNeasy Tissue
Kit (Qiagen). Genotyping PCRs were performed on genomic
DNA in a 25 ml volume with ABgene ReddyMix (ABgene, Epsom,
UK), 150 nmol each of human SOD1 primers (forward 59-CAT-
CAGCCCTAATCCATCTGA-39, reverse 59-CGCGACTAACA-
ATCAAAGTGA-39) and control interleukin-2 receptor (IL-2R)
primers (forward 59-CTAGGCCACAGAATTGAAAGATCT-39,
reverse 59-GTAGGTGGAAATTCTAGCATCATC-39). Follow-
ing PCR and agarose gel electrophoresis (3% agarose gel), IL-2R
PCR products were visualised at 324 bp and human SOD1, if
present at 236 bp.
Mice positive for transgene expression were then subjected to
copy number analysis by quantitative PCR (Q-PCR) using 12.5 ng
cDNA, 16 SYBR Green PCR Master Mix (Applied Biosystems,
Warrington, UK), 2 pmol of human SOD1 primers (forward 59-
CCAAGGAGCAGATCATAGGGC-3; reverse 59-AGAGCATT-
GGAGAAGGCAGG-39) in a total volume of 20 ml. Following an
initial denaturation at 95uC for 10 min, DNA was amplified by 40
cycles of 95uC for 15 sec and 60uC for 1 min, on an MX3000P
Real-Time PCR System (Stratagene). ddCt values were compared
to a reference DNA sample containing only two copies of human
SOD1.
Pharmacology study design
Pharmacology studies have been run in a standard way to allow
comparisons between data sets over time. In general the principles
set out in ‘The design of animal experiments’ by M. Festing were
followed [27]. Power analysis suggested 13–15 mice per group
with two groups (vehicle and active) would detect a difference in
survival ratio of 10% which is widely accepted as biologically
relevant. We did not always achieve this final n number due to
breeding constraints or mice dropping out of studies due to
incorrect genotyping or issues unrelated to development of motor
dysfunction. The breeding colony was maintained at 8–12
breeding males in pairs which increased to 15–20 breeding
males in trios to generate cohorts for therapeutic studies. Cohorts
of mice born 2–3 weeks apart were used in all studies. The litters
were split to enable an even distribution of sex and parentage
between the two comparison groups and the groups randomly
assigned to treatment or control. In all cases the experimental
unit was a single animal. Due to the limitations of combining
male mice, the need to split animals by litter according to
treatment and keeping vehicle and active dosed mice separate,
mice were generally housed singly to ensure all mice had the
same environment. Drugs were dosed without anesthesia as they
were minor procedures where anesthesia would be more
distressing than the administration itself. Mice were bred in a
Specified Pathogen Free facility and transferred to a conventional
unit for pharmacology studies.
Behavioural measures and rotarod test
Behavioural assessment was carried out blinded to treatment
group. Rotarod training was performed over 3 days with 2 trials
per day. Subsequently, the rotarod test was performed once, or
more usually, twice a week at the same time of day, typically in the
afternoon. On each day, mice were tested twice with a rest period
in between tests. The best score was taken for analysis. The
rotarod (Ugo Basile 7650) was set to accelerate from 4 to 40 rpm
in 300 seconds. Latency to fall (s) was recorded in seconds for each
mouse. The test was performed until mice reached a time of ,5 s.
For data analysis we determined the time to reach at least a 20%
decline in rotarod performance, this was calculated with the post-
training baseline as being 100%.
Mice were weighed with every dose or at least weekly and
scored for tremor, hind-limb splay and overall neurological deficit
using a scoring system similar to previous studies [47,48,49]. Mice
were scored three times per week from day 65 until onset and then
at the same time as rotarod tests. Onset was defined as the point at
which defects in hind-limb splay and enhanced tremor were
observed (a score of at least 1 in each category). Tremor scores
were recorded individually for fore-limbs and hind-limbs when
suspending the mouse by the tail. The scores were 0-normal, 1-
mild tremor, 2-moderate tremor, 3- strong tremor. Hind-limb
splay defects were scored at the same time with the splay score
recorded independently for left and right hind-limbs on a scale of
0–4 with 0 representing normal, 1 representing mild defect, 2
moderate, 3 strong and 4 paralysis of hind limb.
From 125 days of age onwards mice were closely monitored and
scored for signs of distress daily, using a standardised distress
scoring system based on appearance, provoked behaviour, weight
loss and an overall neurological score. Provoked behavior is the
behavior observed when the mice are first disturbed, for example
by opening the cage and was scored as follows; 0-normal, bright
and inquisitive mice, 1-mild impairment or exaggeration in
provoked response, 2-a moderate reduction in provoked response
or disinterested mice, 3-a strong reduction in provoked response
and 4-a moribund animal. The neurological score was used to give
a global score of the disease state of the mice for the purpose of
monitoring distress levels and was scored as follows; 0-normal, 0.5-
tremor and hind limb splay defect (onset), 1-abnormal gait, 2-
Partial hind-limb parlysis (first signs of dragging), 3- Hind-limb
paralysis plus forelimb weakness, 4- Significant fore and hind-limb
paralysis.
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This scoring was continued through to the humane end-point,
inability to right within 10 seconds of being placed on their back
or weight loss of .30% for 72 hours. Mice were provided with
wetted mash in their cages from the first signs of hind limb
paralysis and the eyes of mice showing signs of ocular discharge
were bathed daily. At this time, or earlier if necessary, the
bedding material was optimised, to reduce dust and improve ease
of movement. Mice were euthanased with an overdose of
anaesthetic (intraperitoneal injection of approximately 20 ml/kg
pentobarbitone).
Immunofluorescence staining
Mice were euthanized by dislocation of the neck (schedule 1
method following the Code of Practice for the Humane Killing of
Animals under Schedule 1 to the Animals (Scientific Procedures)
Act 1986) and both gastrocnemius muscles were immediately
dissected out. Whole muscles were post-fixed in 4% paraformal-
dehyde for 20 min, followed by cryopreservation through 3
successive 5 minute incubations in 5, 10 and 15% sucrose.
Specimens were incubated overnight in 20% sucrose then
embedded in OCT embedding matrix. Thirty five-micrometer-
thick longitudinal sections were collected on Superfrost Plus Slides
(CML). Tissue sections were dried, permeabilised in blocking
solution (0.5% triton X-100, SIGMA-Aldrich, 5% BSA in PBS) at
37uC for 2 hours. Rabbit polyclonal anti neurofilament 145
(Chemicon) was diluted (1:1000) in the same blocking solution and
incubated at 4uC, overnight. Anti rabbit alexa 488 conjugated
secondary antibody was applied on the sections together with a-
bungarotoxin-tetramethylrhodamine conjugate both at a 1:1000
dilution in PBS; 1%BSA and incubated for 2 hours at room
temperature before washing and mounting using Mowiol
mounting medium. Sections were examined under an Axio
microscope (Zeiss) to visualise stained end-plates. Innervated
(yellow) or denervated (red) end-plates were counted on apoptome
35 mm Z-stacks as described by [2].
Catwalk gait analysis system
The catwalk gait analysis system version 7.1 was used to capture
gait parameters in groups of 5 SOD1G93A transgenic mice and 7
non-transgenic mice. Mice were tested weekly from 5 weeks of age
to 15 weeks of age. They were placed on the catwalk apparatus in
complete darkness and the recording of gait patterns performed in
a separate room. Multiple runs were recorded for each mouse and
three selected for analysis. Processing of gait data was performed
using the dedicated software with the assignment of limbs
performed manually and subsequent automated calculation of
gait parameters.
Stand time is the duration of the stance phase for a particular
limb in seconds, stride length is the distance between consecutive
foot placings in mm and support on diagonal limbs or three limbs
is the percentage of time the mouse spends supporting its weight
on diagonally opposite limbs or on a total of three limbs.
Magnetic resonance imaging
Five female transgenic C57BL/6 SOD1G93A and five age
matched female non-transgenic littermates were blind imaged in a
7 Tesla magnet (Bruker BioSpecAVANCE, 310 mm bore, MRI
system B/C 70/30), with pre-installed 12 channel RT-shim system
(B-S30) and fitted with an actively shielded, 116 mm inner
diameter, water cooled, 3 coil gradient system (Bruker BioSpin
MRI GmbH B-GA12. 400 mT/m maximum strength per axis
with 80 ms ramps) to assess lower hind limb [4] muscle volumes at
postnatal (P) day 30, 60, 90 and 120.
Animals were placed in a custom built Perspex magnet capsule
and imaged under gaseous anaesthesia (1–1.5%, flow rate 0.8–
1.0 L/min continuous inhalation through a nose cone). Anaes-
thetic level was controlled on the basis of respiratory parameters;
monitored using a pressure sensitive pad placed under the subject’s
chest (SAII Model 1025 monitoring and gating system). Inside the
capsule, a non-magnetic ceramic heated hot air system (SAII -
MR-compatible Heater System for Small Animals) and rectal
probe, integrated into the physiological monitoring system
maintained the temperature of the animal. All animals were
euthanized at the 120 day time point.
A 1H birdcage volume resonator (Bruker, 300 MHz, 1 kW max,
outer diameter 114 mm/inner diameter 72 mm), placed at the iso-
centre of the magnet was used for both RF transmission and
reception. A workstation configured for use with ParaVisionTM 4.0
software operated the spectrometer. Following field shimming, off-
resonance correction and RF gain setting a tri-plane FLASH
sequence (TR=100 ms, TE= 6 ms, Flip angle = 30u, Av= 1,
FOV=40 mm*40 mm, Slice thk = 2 mm, Matrix = 128*128)
was used for subject localisation. From this a fast (,5 min) 3D
FISP sequence (TR=8/1200 ms, TE=4 ms, FOV=40 mm*
40 mm*40 mm, Matrix = 256*256*128) allowed low SNR visual-
isation of the hind limb area and thus planning of 21 axial high
SNR single Spin Echo images (TR=3200 ms, TE= 7.5 ms,
Av= 1, FOV=40 mm*40 mm, Slice thk = 1 mm, Matrix =
256*256) covering the entire lower hind limb and pelvic region.
No fat suppression was used to maximise muscle/fat contrast
difference for easy segmentation.
For data processing, a macro built into ParaVision 4.0 was used
for manual segmentation of muscle from fat and bone across all
slices in 3 regions (the left and right hind limb and the pelvic
region). Using the scan FOV setting and the slice thickness allowed
for volume conversion of segmented data.
Statistics
GraphPad Prism version 3.04 was used for all statistical analyses
(GraphPad, San Diego, CA, USA). Time to onset was analysed by
Student’s T test, time to loss of righting reflex by Survival analysis
(logrank method), rotarod and weight data were analysed using
two-way ANOVA. For power analysis GraphPad Statmate or
G*power3 [50] was used. All data are represented as mean and
standard deviation unless otherwise stated.
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